Brokerages Set NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Target Price at $38.00

Shares of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) have been given an average rating of “Moderate Buy” by the six analysts that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $38.00.

A number of equities analysts have recently commented on NRXP shares. Ascendiant Capital Markets reissued a “buy” rating and set a $48.00 price target (up from $47.00) on shares of NRx Pharmaceuticals in a report on Friday, January 2nd. Wall Street Zen upgraded NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, November 23rd. BTIG Research reissued a “buy” rating and issued a $25.00 target price on shares of NRx Pharmaceuticals in a report on Wednesday, February 18th. Zacks Research upgraded shares of NRx Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, March 2nd. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of NRx Pharmaceuticals in a report on Monday, December 29th.

Institutional Trading of NRx Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of NRXP. Geode Capital Management LLC increased its holdings in shares of NRx Pharmaceuticals by 27.9% during the second quarter. Geode Capital Management LLC now owns 172,255 shares of the company’s stock worth $562,000 after buying an additional 37,598 shares in the last quarter. Ethos Financial Group LLC bought a new stake in NRx Pharmaceuticals during the 3rd quarter worth $39,000. One Wealth Management Investment & Advisory Services LLC grew its position in NRx Pharmaceuticals by 86.1% during the 3rd quarter. One Wealth Management Investment & Advisory Services LLC now owns 27,991 shares of the company’s stock worth $92,000 after acquiring an additional 12,950 shares during the last quarter. AdvisorShares Investments LLC increased its holdings in NRx Pharmaceuticals by 29.7% in the 3rd quarter. AdvisorShares Investments LLC now owns 342,136 shares of the company’s stock worth $1,129,000 after purchasing an additional 78,339 shares in the last quarter. Finally, Vanguard Group Inc. increased its holdings in NRx Pharmaceuticals by 18.3% in the 3rd quarter. Vanguard Group Inc. now owns 534,956 shares of the company’s stock worth $1,765,000 after purchasing an additional 82,781 shares in the last quarter. Institutional investors own 4.27% of the company’s stock.

NRx Pharmaceuticals Stock Performance

Shares of NRXP stock opened at $1.85 on Wednesday. The stock’s fifty day moving average price is $1.95 and its two-hundred day moving average price is $2.45. The company has a market cap of $58.96 million, a PE ratio of -0.79 and a beta of 1.97. NRx Pharmaceuticals has a fifty-two week low of $1.58 and a fifty-two week high of $3.84.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.